Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ORIC PHARMACEUTICALS INC (ORIC) Stock Price & Overview
NASDAQ:ORIC • US68622P1093
Current stock price
9.65 USD
-0.54 (-5.3%)
At close:
9.72 USD
+0.07 (+0.73%)
After Hours:
The current stock price of ORIC is 9.65 USD. Today ORIC is down by -5.3%. In the past month the price decreased by -20.84%. In the past year, price increased by 70.19%.
ORIC Key Statistics
52-Week Range4.52 - 14.93
Current ORIC stock price positioned within its 52-week range.
1-Month Range7.23 - 13.04
Current ORIC stock price positioned within its 1-month range.
- Market Cap
- 968.474M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.52
- Dividend Yield
- N/A
ORIC Stock Performance
Today
-5.3%
1 Week
-9.22%
1 Month
-20.84%
3 Months
-5.95%
Longer-term
6 Months -26.67%
1 Year +70.19%
2 Years +9.29%
3 Years +86.65%
5 Years -60.01%
10 Years N/A
ORIC Stock Chart
ORIC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ORIC. When comparing the yearly performance of all stocks, ORIC is one of the better performing stocks in the market, outperforming 85.31% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ORIC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORIC. While ORIC has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ORIC Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateFeb 23, 2026
PeriodQ4 / 2025
EPS Reported-$0.30
Revenue Reported
EPS Surprise 19.17%
Revenue Surprise %
ORIC Forecast & Estimates
21 analysts have analysed ORIC and the average price target is 21.42 USD. This implies a price increase of 121.97% is expected in the next year compared to the current price of 9.65.
Analysts
Analysts86.67
Price Target21.42 (121.97%)
EPS Next Y5.42%
Revenue Next YearN/A
ORIC Index Membership
ORIC is currently included in the following stock indexes tracked on ChartMill.
ORIC Financial Highlights
Over the last trailing twelve months ORIC reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 16.48% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-129.47M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.66% | ||
| ROE | -33.68% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%41.18%
Sales Q2Q%N/A
EPS 1Y (TTM)16.48%
Revenue 1Y (TTM)N/A
ORIC Ownership
Ownership
Inst Owners113.29%
Shares100.36M
Float90.07M
Ins Owners1.27%
Short Float %23.03%
Short Ratio10.21
ORIC Industry Overview
ORIC operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
ORIC Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.33 | 349.666B | ||
| AMGN | AMGEN INC | 14.87 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.37 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 24.944B | ||
| INCY | INCYTE CORP | 10.7 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ORIC
Company Profile
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 104 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Company Info
IPO: 2020-04-24
ORIC PHARMACEUTICALS INC
240 E. Grand Ave, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Jacob M. Chacko
Employees: 104
Phone: 13026587581
ORIC PHARMACEUTICALS INC / ORIC FAQ
Can you describe the business of ORIC PHARMACEUTICALS INC?
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 104 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Can you provide the latest stock price for ORIC PHARMACEUTICALS INC?
The current stock price of ORIC is 9.65 USD. The price decreased by -5.3% in the last trading session.
What is the dividend status of ORIC PHARMACEUTICALS INC?
ORIC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ORIC stock?
ORIC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of ORIC stock?
ORIC PHARMACEUTICALS INC (ORIC) has a market capitalization of 968.47M USD. This makes ORIC a Small Cap stock.
Can you provide the upcoming earnings date for ORIC PHARMACEUTICALS INC?
ORIC PHARMACEUTICALS INC (ORIC) will report earnings on 2026-05-11.